-
Mashup Score: 13SIRPass The Summit! - 2 month(s) ago
The SIR Annual Meeting welcomes medical students, residents, and early-career IRs to engage and present their research.
Source: i.snoball.itCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5FDA Approves HEPZATO KIT for Unresectable Hepatic-Dominant Metastatic Uveal Melanoma - 9 month(s) ago
The FDA has approved HEPZATO KIT (melphalan/Hepatic Delivery System) for use in the treatment of select patients with unresectable hepatic-dominant metastatic uveal melanoma.
Source: www.onclive.comCategories: Hem/Oncs, Latest HeadlinesTweet-
🗣️Congrats to Delcath for persistence with this treatment option! Late night waiting for news 📰 🎊Dr. Jon Zager @MoffittNews leading this effort in U.S.🌟 FDA Approves HEPZATO KIT for Hepatic-Dominant Metastatic #Uveal Melanoma https://t.co/KXL0bu4jyv via @onclive
-
-
Mashup Score: 1HOME - 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® - 10 month(s) ago
19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®.
Source: event.gotoper.comCategories: Latest Headlines, Oncologists1Tweet-
RT @OmidHamidMD: https://t.co/anqdh0QqtR CODE: HAMID for free reg @TXHealthSurgery @TexasHealthy @texashealth @CHWhiteRock @DallasEMed @Chi…
-
-
Mashup Score: 14
AbstractPurpose:. Impaired MHCI-presentation and insensitivity to immune effector molecules are common features of immune checkpoint blockade (ICB)-resistant tumors and can be, respectively, associated with loss of β2 microglobulin (B2M) or impaired IFNγ signaling. Patients with ICB-resistant tumors can respond to alternative immunotherapies, such as infusion of autologous tumor-infiltrating…
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @DoniaMarco: 🌟 Did you know CD4+ T cells can kill #immunotherapy-resistant #cancer? 👉 https://t.co/mPj9S5npwN published by @CCR_AACR 🎯…
-
-
Mashup Score: 2Neoadjuvant Therapy in Malignant Melanoma - The ASCO Post - 1 year(s) ago
Transcript Disclaimer: This video transcript has not been proofread or edited and may contain errors. Dr. Omid Hamid: Welcome to The ASCO Post Roundtable Series on Updates in Melanoma. I’m Dr. Omid Hamid, Chief of Translational Research and Immunooncology at The Angeles Clinic and Research Institute, and Co-Director of Cutaneous Malignancies at Cedar Sinai Medical…
Source: ascopost.comCategories: Latest Headlines, Oncologists1Tweet-
RT @ASCOPost: Updates in Melanoma, Part 2: Neoadjuvant Therapy in Malignant Melanoma https://t.co/fdO3xsBCcJ #melsm #skcsm #melanoma @OmidH…
-
-
Mashup Score: 1Melanoma ESMO 2022 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Sapna Patel - 2 year(s) ago
Discussing Melanoma ESMO 2022 Highlights – Practice changing studies with Dr. Sapna Patel, Director of Uveal Melanoma, Program Director of Melanoma Fellowshi…
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
Such an honor and pleasure to talk to 2 of the best in the biz- @OncBrothers helping all of us makes sense of practice changing data in oncology 📈📉🩺 For a brief review of @SWOG #S1801, IMMUNED, & SECOMBIT, check out the podcast: https://t.co/PFHvejNrxJ https://t.co/qzGT3mKU9K
-
-
Mashup Score: 5SWOG S1801: Neoadjuvant Pembrolizumab Improves Event-Free Survival in Stage III-IV Melanoma - 2 year(s) ago
Results from the phase 2 SWOG S1801 trial showed that neoadjuvant pembrolizumab led to better event-free survival (EFS) compared with adjuvant pembrolizumab.
Source: ASCO Daily NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
📰🗣️@SWOG #S1801: Neoadjuvant Pembrolizumab Improves Event-Free Survival in Stage III-IV Melanoma @ASCO Daily News #frontpage #readallaboutit #neoadjuvant #melanoma #melsm 🗞️ https://t.co/AB5AvkcHes 🤳 @NCICancerTrials @EladSharonMD - THANK YOU 🧵 (1/4)
-
-
Mashup Score: 1
Presentations at the ESMO Congress 2022 have demonstrated the critical importance of therapy sequence for locally advanced cancer.
Source: Pharmaceutical TechnologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Thank you for using so many direct quotes from my presentation - word for word, just missing the “ “ #ESMO22: neoadjuvant or adjuvant immunotherapy for locally advanced cancers? https://t.co/Ajnps8QrM3 via @PharmaTechFocus
-
-
Mashup Score: 0SUMMARY - OncLive/Institutional Perspectives in Cancer/Skin Cancer/September 20, 2022/CT - 2 year(s) ago
OncLive® Institutional Perspectives in Cancer: Disease State, Month Day, Year. Oncology Webinar features research and clinical advances in oncology.
Source: event.onclive.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Got 90 minutes on Sept 20? 🔜Come virtually hear institutional perspectives on #melanoma and skin cancers incl #uveal melanoma - worth it to hear evidence-based & cutting edge research in a flash, plus chance to win AirPods! 📢https://t.co/3RQ1uifW66 🪩@OncLive @MDAndersonNews https://t.co/1S7wtSPKX3
-
-
Mashup Score: 0
The Specialized Programs of Research Excellence, or SPORE, grant from the National Cancer Institute will fund three new melanoma research projects over five years.
Source: Penn TodayCategories: Latest Headlines, Oncologists1Tweet-
Congrats @AmaravadiRavi @HerlynLab @PennCancer and @TheWistar for your skin #SPORE from @theNCI $11.7 million #melanoma research grant #InterSPORE cheers! #melsm #endcancer https://t.co/xMrMnKcUCi
-
I'm speaking at #SIR24SLC next Monday March 25, 2024 - med onc perspective! Join the ultimate IR conf: 4 days core programming, 30+ scientific sessions, 130+ educational sessions, and more! 🚀 Register today for the largest IR event of the year! #IRad https://t.co/YTOFgYOa3H